These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 17939581

  • 1. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L, Brito D, Matias JS, Madeira H.
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [Abstract] [Full Text] [Related]

  • 2. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
    Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E, Degiannis D, Kremastinos DT.
    Int J Cardiol; 2005 Mar 30; 99(3):409-13. PubMed ID: 15771921
    [Abstract] [Full Text] [Related]

  • 4. Hemodynamic improvement of acutely decompensated heart failure patients is associated with decreasing levels of NT-proBNP.
    Knebel F, Schimke I, Diaz Ramirez I, Schattke S, Eddicks S, Borges AC, Baumann G.
    Int J Cardiol; 2009 May 15; 134(2):260-3. PubMed ID: 18384896
    [Abstract] [Full Text] [Related]

  • 5. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B.
    J Card Fail; 2007 Aug 13; 13(6):417-21. PubMed ID: 17675054
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T.
    Eur J Heart Fail; 2008 Dec 13; 10(12):1246-54. PubMed ID: 18945637
    [Abstract] [Full Text] [Related]

  • 11. Correlation of B type natriuretic peptides with clinical and echocardiographic parameters in heterogeneous population of patients with symptoms suggestive of heart failure.
    Piechota WN, Piechota WT, Bejm J, Wierzbowski R, Michałkiewicz D.
    Adv Med Sci; 2006 Dec 13; 51():164-7. PubMed ID: 17357300
    [Abstract] [Full Text] [Related]

  • 12. Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment.
    Giglioli C, Cecchi E, Landi D, Chiostri M, Spini V, Valente S, Gensini GF, Romano SM.
    Congest Heart Fail; 2012 Dec 13; 18(1):47-53. PubMed ID: 22277178
    [Abstract] [Full Text] [Related]

  • 13. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay.
    Lee-Lewandrowski E, Januzzi JL, Green SM, Tannous B, Wu AH, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS.
    Clin Chim Acta; 2007 Dec 13; 386(1-2):20-4. PubMed ID: 17854790
    [Abstract] [Full Text] [Related]

  • 14. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E, Erturk M, Birant A, Kurtar Mansıroglu A, Akturk IF, Karakurt H, Yalcin AA, Uzun F, Somuncu MU, Yildirim A.
    Cardiol J; 2015 Dec 13; 22(1):87-93. PubMed ID: 24846511
    [Abstract] [Full Text] [Related]

  • 15. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 16. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.
    Cardiovasc Ther; 2013 Apr 23; 31(2):108-14. PubMed ID: 23490237
    [Abstract] [Full Text] [Related]

  • 17. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O, Paz H, Ammar R, Yaniv N, Schliamser JE, Lewis BS.
    Isr Med Assoc J; 2008 Feb 23; 10(2):109-12. PubMed ID: 18432021
    [Abstract] [Full Text] [Related]

  • 18. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan 23; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 19. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT.
    Am J Cardiol; 2006 Dec 15; 98(12):1641-5. PubMed ID: 17145226
    [Abstract] [Full Text] [Related]

  • 20. The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure.
    Zdrenghea D, Pop D, Ilea M, Bodisz G, Mălai A, Zdrenghea M.
    Rom J Intern Med; 2009 Dec 15; 47(1):35-40. PubMed ID: 19886067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.